论文部分内容阅读
目的分析丹红注射液、氯吡格雷与奥扎格雷钠治疗急性脑梗死的疗效和安全性。方法选取发病在24 h的急性脑梗死患者100例,按随机数字分成治疗组(50例)及对照组(50例),治疗组给予丹红注射液160 mg、奥扎格雷钠80 mg静脉滴注+口服氯吡格雷75 mg,1次/d;对照组仅用同疗程、同剂量的奥扎格雷钠、氯吡格雷。结果采用临床神经功能缺损程度评分对疗效进行评估结果治疗组显效34例(68%),总有效47例(90%);对照组显效27例(54%),总有效38例(76%)。两组比较差异有统计学意义(P<0.05)。结论两组均未见明显不良反应结论丹红注射液、氯吡格雷与奥扎格雷钠治疗急性脑梗死安全有效。
Objective To analyze the efficacy and safety of Danhong injection, clopidogrel and ozagrel sodium in the treatment of acute cerebral infarction. Methods A total of 100 acute cerebral infarction patients with onset of 24 h were randomly divided into treatment group (n = 50) and control group (n = 50). The treatment group was given Danhong injection 160 mg and ozagrel 80 mg intravenously Note + oral clopidogrel 75 mg, 1 / d; control group only with the same course of treatment, the same dose of ozagrel sodium, clopidogrel. Results The clinical efficacy of neurological deficit score was evaluated in 34 cases (68%) and 47 cases (90%) in the treatment group. In the control group, 27 cases (54%) were markedly effective and 38 cases (76%) were effective. . The difference between the two groups was statistically significant (P <0.05). Conclusion No adverse reactions were observed in both groups. Conclusion Danhong injection, clopidogrel and ozagrel sodium are safe and effective in the treatment of acute cerebral infarction.